Breast cancer drug schedule showdown: continuous vs. intermittent dosing
NCT ID NCT07180082
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two ways of taking the drug pyrotinib for people with HER2-positive advanced breast cancer: taking it every day (continuous) or taking breaks (intermittent). The goal is to see which schedule works better and has fewer side effects. About 186 adults whose cancer has spread or cannot be removed by surgery will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITINGShanghai, 200127, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can a pill combo outpace chemotherapy for aggressive breast cancer?
- Blood tests could reveal hidden resistance in breast cancer
- Triple threat: three new targeted drugs join forces with immunotherapy to attack Hard-to-Treat breast cancer
- AI tool aims to predict breast cancer drug success, sparing patients unnecessary side effects
- New drug sequence aims to outsmart advanced breast cancer